Statistical analysis We did not perform power calculations, but the sample size and animal number for each group were chosen based on study feasibility and prior knowledge of statistical power from previously published experiments
We observed that 11.8% of tirzepatide-treated rs1800437-CC carrier individuals experienced vomiting, compared with 9.4% for semaglutide-treated people carrying the same genotype, although the difference was not significant ( P = 0.12, two-sample z -test
Setting honest expectations
Through its effects on mitochondria, gentamicin triggers the intrinsic process of cell death
Cch bo qun sn phm S dng ngay sau khi m np ng thi ng np khi khng s dng sn phm
PCOS and GLP-1s: Improving Reproductive Functionality For PCOS, the human evidence on GLP-1 medications is compelling enough that they now feature in the 2023 International PCOS Guidelines, though as a conditional recommendation (1)